For research use only. Not for therapeutic Use.
Seletalisib（Cat No.:I009212）is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ), an enzyme involved in immune cell signaling, particularly in B-cells and T-cells. By targeting PI3Kδ, Seletalisib modulates immune responses, making it a promising candidate for treating autoimmune and inflammatory diseases, such as primary Sjögren’s syndrome and rheumatoid arthritis. It helps regulate abnormal immune activation, reducing inflammation and tissue damage. Seletalisib’s specificity for PI3Kδ offers a therapeutic advantage by minimizing off-target effects seen with broader PI3K inhibitors, enhancing its potential as a safe and effective immunomodulatory drug.
| Catalog Number | I009212 |
| CAS Number | 1362850-20-1 |
| Synonyms | UCB-5857; UCB 5857; UCB5857; Seletalisib.;(R)-3-(8-chloro-3-(2,2,2-trifluoro-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)quinolin-2-yl)pyridine 1-oxide |
| Molecular Formula | C23H14ClF3N6O |
| Purity | ≥95% |
| Target | PI3K |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | N-[(1R)-1-[8-chloro-2-(1-oxidopyridin-1-ium-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-amine |
| InChI | InChI=1S/C23H14ClF3N6O/c24-16-6-1-4-13-10-15(18(31-19(13)16)14-5-3-9-33(34)11-14)21(23(25,26)27)32-22-20-17(29-12-30-22)7-2-8-28-20/h1-12,21H,(H,29,30,32)/t21-/m1/s1 |
| InChIKey | LNLJHGXOFYUARS-OAQYLSRUSA-N |
| SMILES | C1=CC2=CC(=C(N=C2C(=C1)Cl)C3=C[N+](=CC=C3)[O-])[C@H](C(F)(F)F)NC4=NC=NC5=C4N=CC=C5 |
| Reference | </br>1:Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K<i>δ</i>. Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A.J Pharmacol Exp Ther. 2017 Jun;361(3):429-440. doi: 10.1124/jpet.116.237347. Epub 2017 Apr 25. PMID: 28442583 Free Article</br>2:First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, Payne A, Koch A, Healy E.Eur J Clin Pharmacol. 2017 May;73(5):581-591. doi: 10.1007/s00228-017-2205-7. Epub 2017 Feb 4. PMID: 28160012 Free PMC Article |
